Single-molecule methylation profiles of cell-free DNA in cancer with nanopore sequencing.

Autor: Lau BT; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., Almeda A; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., Schauer M; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., McNamara M; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., Bai X; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., Meng Q; Department of Electrical Engineering, Stanford University, Stanford, CA, USA., Partha M; Department of Electrical Engineering, Stanford University, Stanford, CA, USA., Grimes SM; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., Lee H; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., Heestand GM; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA., Ji HP; Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA. genomics_ji@stanford.edu.; Department of Electrical Engineering, Stanford University, Stanford, CA, USA. genomics_ji@stanford.edu.
Jazyk: angličtina
Zdroj: Genome medicine [Genome Med] 2023 May 03; Vol. 15 (1), pp. 33. Date of Electronic Publication: 2023 May 03.
DOI: 10.1186/s13073-023-01178-3
Abstrakt: Epigenetic characterization of cell-free DNA (cfDNA) is an emerging approach for detecting and characterizing diseases such as cancer. We developed a strategy using nanopore-based single-molecule sequencing to measure cfDNA methylomes. This approach generated up to 200 million reads for a single cfDNA sample from cancer patients, an order of magnitude improvement over existing nanopore sequencing methods. We developed a single-molecule classifier to determine whether individual reads originated from a tumor or immune cells. Leveraging methylomes of matched tumors and immune cells, we characterized cfDNA methylomes of cancer patients for longitudinal monitoring during treatment.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje